Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T Status
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Beta blockers (BB) play an important role in protection of end organs that are susceptible
for secondary injury by the Traumatic brain injury (TBI)-induced catecholamine surge.
However, use of BBs in trauma patients is not yet the standard of care which necessitates
clear scientific evidence and justification to be used especially in TBI patients. The BBTBBT
study aims to determine whether early administration of propranolol based on the HSTnT status
will improve the outcome of mild-to-severe TBI patients. Our primary hypothesis is that BBs
are effective in reducing 10 and 30-day mortality in TBI patients.BBs are effective in
reducing 10 and 30-day mortality in TBI patients.
Methods/Design: The BBTBBT study is a prospective, randomized, double-blinded,
placebo-controlled trial, three-arm trial of BB use in mild-to-severe TBI patients based on
the HsTnT status.